CN Patent

CN116421590B — 二乙酸氯己定在制备预防或/和治疗肝癌的药物中的用途

Assigned to Shenzhen Second Peoples Hospital · Expires 2023-08-29 · 3y expired

What this patent protects

本申请涉及一种二乙酸氯己定的新用途，具体涉及二乙酸氯己定在制备预防或/和治疗肝癌的药物中的用途。进一步地，所述的肝癌细胞为SNU449。与传统技术相比，本申请具备如下有益效果：本申请首次将二乙酸氯己定应用于制备预防或/和治疗肝癌的药物。发明人发现，二乙酸氯己定能够特异性抑制肝癌细胞增殖，通过抑制RNA解旋酶DDX17，有望成为攻克肝癌的新型药物。

USPTO Abstract

本申请涉及一种二乙酸氯己定的新用途，具体涉及二乙酸氯己定在制备预防或/和治疗肝癌的药物中的用途。进一步地，所述的肝癌细胞为SNU449。与传统技术相比，本申请具备如下有益效果：本申请首次将二乙酸氯己定应用于制备预防或/和治疗肝癌的药物。发明人发现，二乙酸氯己定能够特异性抑制肝癌细胞增殖，通过抑制RNA解旋酶DDX17，有望成为攻克肝癌的新型药物。

Drugs covered by this patent

Patent Metadata

Patent number
CN116421590B
Jurisdiction
CN
Classification
—
Expires
2023-08-29
Drug substance claim
No
Drug product claim
No
Assignee
Shenzhen Second Peoples Hospital
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.